Pharma News

Narayana Hrudayalaya Tissue Bank & Stem Cell Research Centre to invest Rs 1.50 cr for expansion

Narayana Hrudayalaya Tissue Bank and Stem Cell Research Centre (NHTB-SCRC) has slated an investment of Rs 1.50 crore for the facility expansion this year. The Centre which commenced operations in October 2009, now intends to further increase its research efforts in chord cell therapies. The facility now requires additional storage and processing units for the same. The expansion will be underway by June this year.

GSKs CAT to help COPD patients better manage their chronic lung disease

Singapore, Mar 30, 2010: A new and simple test to help patients cope better with COPD, a chronic lung disease is being launched to local medical practitioners of Singapore. Experts now hope the COPD Assessment Test (CAT) that was funded by GlaxoSmithKline (GSK) and is freely available for use, will be a significant breakthrough in efforts to reduce the burden of one of the world’s most debilitating diseases.

US president Obama signs Indian Health Care Improvement Act

The Indian Health Care Improvement Act (IHCIA), the cornerstone legal authority for the provision of health care to American Indians and Alaska Natives, was made permanent when President Obama signed the bill on March 23, as part of the Patient Protection and Affordable Care Act. The authorization of appropriations for the IHCIA had expired in 2000, and while various versions of the bill were considered by Congress since then, the act now has no expiration date.

Centre approves establishment of Indo-German Science & Technology Centre in India

The central government has approved the establishment of Indo-German Science and Technology Centre (IGSTC) in India with matching contribution as per Expenditure Finance Committee (EFC) approval of 2 million Euro (approximately Rs 13 crore at current exchange rates) per year for next five years. The Centre would be registered as a “Society” under the relevant Act.

Antithrombotic Therapy Does Not Improve Outcomes in Recurrent Miscarriage

 In women with 2 or more unexplained miscarriages, aspirin therapy alone or in combination with the low-molecular-weight heparin derivative nadroparin does not increase the live-birth rate, relative to placebo, despite its widespread use for this purpose.

That is according to the randomized placebo-controlled Anticoagulants for Living Fetuses (ALIFE) study, published online March 24 in the New England Journal of Medicine.

Poniard Pharma suspends efforts to obtain regulatory approval for picoplatin in SCLC

 Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, announced a clinical and regulatory update on its lead product candidate, picoplatin. Following a detailed analysis of primary and updated data from the phase 3 SPEAR study of picoplatin in small cell lung cancer (SCLC) and an evaluation of the ongoing New Drug Application (NDA) process with the US Food and Drug Administration (FDA), the company has decided to suspend its efforts to obtain regulatory approval for picoplatin in SCLC at this time.

NIH creates new genetic testing registry to help researchers, consumers & healthcare providers

 The National Institutes of Health (NIH) announced that it is creating a public database that researchers, consumers, health care providers, and others can search for information submitted voluntarily by genetic test providers. The Genetic Testing Registry (GTR) aims to enhance access to information about the availability, validity, and usefulness of genetic tests.

Pages